Recent News

• 10.03.2025 - Ryoncil Receives CMS (Medicaid) J-Code for Reimbursement
• 09.26.2025 - Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
• 09.22.2025 - Ceasing to be a substantial holder
• 09.16.2025 - Becoming a substantial holder
• 09.16.2025 - Becoming a substantial holder
• 09.15.2025 - Ceasing to be a substantial holder
• 09.14.2025 - Ryoncil Launch Highlighted at Global Healthcare Conferences
• 09.12.2025 - Change of Director's Interest Notice
• 09.12.2025 - Change in substantial holding

Recent Filings

• 10.03.2025 - EX-99.1 EX-99.1
• 10.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2025 - EX-99.1 EX-99.1
• 09.16.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.15.2025 - EX-99.1 EX-99.1
• 09.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.15.2025 - EX-99.1 EX-99.1
• 09.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors